Focus on Prostate Cancer Mdxhealth is sharpening its focus on prostate cancer diagnostics, demonstrated by its strategic divestment from the Resolve UTI testing business and closure of its Texas laboratory. This targeted approach highlights opportunities to deepen collaborations with healthcare providers specializing in prostate cancer management.

Strong Market Position With a revenue range of 50 to 100 million dollars and strategic data presentations at industry events like EAU 2026, Mdxhealth is establishing itself as a key player in precision diagnostics. This presents avenues for sales teams to offer expanded molecular testing solutions to urology and oncology clinics.

Innovative Technology Stack Utilizing advanced molecular technologies and cloud-based analytics such as Microsoft Azure, Google Analytics, and proprietary genetic and epigenetic testing, Mdxhealth provides unique diagnostic data. Partnerships and integrations with tech vendors and healthcare IT systems could drive new sales channels.

Robust Clinical Data The company's demonstration of the Genomic Prostate Score's predictive power across multiple treatment settings signifies its clinical credibility. This opens opportunities to directly target urologists and oncologists seeking proven, data-driven diagnostic tools.

European and US Operations With headquarters in Irvine, California, and operations across Europe including Belgium and the Netherlands, Mdxhealth's international footprint allows for cross-market expansion initiatives. Global sales efforts can leverage this geographic presence to grow customer base and distribution partnerships.